Emergency Department, First Hospital of Jilin University, Changchun, Jilin Province, China.
Department of Endocrinology and Nephrology, Central Hospital of Tonghua, Tonghua, Jilin Province, China.
Curr Pharm Des. 2020;26(27):3332-3340. doi: 10.2174/1381612826666200303114955.
Cerebral ischemia-reperfusion injury is an extremely complicated pathological process that is clinically characterized by high rates of disability and mortality. It is imperative to explore some effective neuroprotective agents for its treatment. Ulinastatin is a protease inhibitor with anti-inflammatory and antioxidant activity. For the past few years, new studies of ulinastatin for the treatment of ischemic brain injury have emerged.
We conducted a review to summarize the mechanisms of ulinastatin and analyze its neuroprotective action against cerebral ischemia-reperfusion injury.
We reviewed and summarized pertinent reports published between 1993 and 2019 from PubMed, Web of Science, and Embaseby searching for the scientific terms ulinastatin, cerebral ischemia-reperfusion injury, neuroprotective, stroke, cardiac arrest, and brain edema.
The protective mechanisms of ulinastatin in the key steps of cerebral ischemia-reperfusion injury include inhibition of inflammatory response, oxidative stress, neuronal apoptosis, neuronal autophagy, and aquaporin- 4 expression as well as improvement in blood-brain barrier permeability. In addition, we provide a perspective on potential research directions and clinical safety.
Ulinastatin seems to have the potential to alleviate cerebral ischemia-reperfusion injury. These findings may be valuable to further promote the research and development of drug candidates and provide novel and reliable references for rational drug use.
脑缺血再灌注损伤是一种极其复杂的病理过程,其临床特征为高残疾率和高死亡率。因此,迫切需要探索一些有效的神经保护剂来治疗它。尿胰蛋白酶抑制剂具有抗炎和抗氧化活性。近年来,人们对尿胰蛋白酶抑制剂治疗缺血性脑损伤进行了新的研究。
我们对尿胰蛋白酶抑制剂的作用机制进行综述,并分析其对脑缺血再灌注损伤的神经保护作用。
我们检索了 1993 年至 2019 年间在 PubMed、Web of Science 和 Embase 上发表的相关报告,使用的检索词为尿胰蛋白酶抑制剂、脑缺血再灌注损伤、神经保护、中风、心脏骤停和脑水肿。
尿胰蛋白酶抑制剂在脑缺血再灌注损伤的关键步骤中的保护机制包括抑制炎症反应、氧化应激、神经元凋亡、神经元自噬和水通道蛋白 4 的表达以及改善血脑屏障通透性。此外,我们还提供了对潜在研究方向和临床安全性的看法。
尿胰蛋白酶抑制剂似乎有减轻脑缺血再灌注损伤的潜力。这些发现可能对进一步促进候选药物的研究和开发有价值,并为合理用药提供新的可靠参考。